1,793 reports of this reaction
6.3% of all ROTIGOTINE reports
#1 most reported adverse reaction
PRODUCT ADHESION ISSUE is the #1 most commonly reported adverse reaction for ROTIGOTINE, manufactured by UCB, Inc.. There are 1,793 FDA adverse event reports linking ROTIGOTINE to PRODUCT ADHESION ISSUE. This represents approximately 6.3% of all 28,260 adverse event reports for this drug.
Patients taking ROTIGOTINE who experience product adhesion issue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT ADHESION ISSUE is moderately reported among ROTIGOTINE users, representing a notable but not dominant share of adverse events.
In addition to product adhesion issue, the following adverse reactions have been reported for ROTIGOTINE:
The following drugs have also been linked to product adhesion issue in FDA adverse event reports:
PRODUCT ADHESION ISSUE has been reported as an adverse event in 1,793 FDA reports for ROTIGOTINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT ADHESION ISSUE accounts for approximately 6.3% of all adverse event reports for ROTIGOTINE, making it one of the most commonly reported side effect.
If you experience product adhesion issue while taking ROTIGOTINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.